Group 1 - The company announced its first quarter operational performance for the decoration business in 2025, highlighting the need for investors to distinguish between signed but uncompleted contracts and previously reported figures [1][4][10] - The company will not distribute cash dividends, issue bonus shares, or convert reserves into share capital for the 2024 fiscal year [8][16][49] - The company has received a high-tech enterprise certificate, indicating its commitment to innovation and technology [10][46] Group 2 - The company plans to apply for a comprehensive credit line from banks for 2025, with a limit of up to 2.5 billion yuan, to support its operational activities [14][49] - The company held its second board meeting of 2025 on April 27, where several key reports and proposals were approved, including the annual report and the internal control self-evaluation report [13][46][48] - The annual shareholders' meeting is scheduled for May 23, 2025, where various proposals will be presented for approval [19][21][28]

Core Viewpoint - The supervisory board of Hualan Biological Engineering Co., Ltd. held its 15th meeting of the 8th session, approving several key proposals including the annual report, profit distribution plan, and changes in accounting policies, all of which will be submitted for shareholder approval at the upcoming annual general meeting [1][2][3]. Meeting Overview - The meeting was held on March 28, 2025, with all three supervisory board members present, complying with legal and regulatory requirements [1]. Resolutions Passed - The supervisory board approved the 2024 Annual Work Report, which will be submitted for shareholder review [2]. - The 2024 Annual Report and its summary were also approved, confirming that the report accurately reflects the company's situation without any misleading statements [2]. - The 2024 Financial Settlement Report was approved, pending shareholder approval [2]. - A profit distribution plan was approved, proposing a cash dividend of 2 yuan per 10 shares, totaling approximately 365.76 million yuan, with remaining undistributed profits rolling over to the next year [2][3]. - Changes to accounting policies and estimates were approved, ensuring compliance with the latest accounting standards without significantly impacting the company's financial status [3][4]. - The 2024 Internal Control Self-Evaluation Report was approved, indicating a robust internal control system in place [4]. - The proposal to use idle funds for investment and financial management was approved, aimed at improving fund utilization efficiency [5]. - The reappointment of the auditing firm for 2025 was approved, pending shareholder approval [5]. - The proposal to repurchase and cancel certain restricted stock options from the 2023 incentive plan was approved, ensuring compliance with relevant regulations [6]. - A proposal to amend the company's registered capital and related articles in the Articles of Association was approved, pending shareholder approval [6][7]. - The establishment of a Public Opinion Management System and a Market Value Management System was approved [7].